APP下载

曲美他嗪联合参麦注射液对充血性心衰患者的疗效观察

2017-04-06周杨张赟华

中国现代医生 2017年2期

周杨+张赟华

[摘要] 目的 探讨曲美他嗪联合参麦注射液治疗充血性心衰的临床疗效及对患者血浆NT-proBNP的影响。 方法 选取2014年1月~2016年2月本科收治的心衰患者66例,随机分为治疗组和对照组。对照组28例患者给予常规抗心衰药物治疗,治疗组38例患者在此基础上加用曲美他嗪联合参麦注射液治疗,进而对疗效进行测评。结果 治疗组有效率为94.74%,高于对照组的71.43%(P<0.01);治疗后两组患者血浆NT-proBNP水平、LVSD、LVDD明显降低,LVEF显著升高,但治疗组NT-proBNP、LVSD、LVEF改善更为明显,差异有统计学意义(P<0.05)。结论 曲美他嗪联合参麦注射液治疗充血性心力衰竭,可改善患者心功能状况,降低患者血浆NT-proBNP水平。

[关键词] 充血性心衰;曲美他嗪;参麦注射液;NT-proBNP

[中图分类号] R541.6 [文献标识码] A [文章编号] 1673-9701(2017)02-0027-03

Efficacy of trimetazitine combining with ShenMai injection in patients with congestive heart failure

ZHOU Yang ZHANG Yunhua

ICU,Traditional Chinese Medical Hospital of ZhuJi City in Zhejiang Province, Zhuji 311800, China

[Abstract] Objective To investigate the clinical efficacy of trimetazidine combined with ShenMai injection in the treatment of patients with congestive heart failre and the effect on plasma NT-proBNP of patients. Methods A total of 66 heart failure patients who were treated in our department from January 2014 to February 2016 were selected, randomly divided into treatment group and control group. 28 patients in the control group were given routine anti heart failure drug treatment, while 38 patients in the treatment group were given the additional therapy of trimetazidine combined with ShenMai injection. Then the curative effect can be evaluated. Results The treatment effective rate was 94.74% in the treatment group, higher than that in the control group(71.43%). After the treatment,plasma NT-proBNP、LVSD、LVDD were reduced, and LVEF was increased in both of the groups. But the improvement of NT-proBNP, LVSD, LVEF were more significant in the treatment group, and the differences were statistically significant(P<0.05). Conclusion The combined application of trimetazitine combining with ShenMai injection is able to significantly reduce the plasma NT-proBNP in patients with congestive heart failure, and is able to significantly improve the cardiac function.

[Key Words] Congestive heart failure; Trimetazitine; ShenMai injection; NT-proBNP

急性失代偿性充血性心力衰竭是ICU常见疾病,也是主要死亡原因之一。研究表明[1-3]NT-proBNP水平与患者心功能损害程度密切相关,对评价心衰严重程度及判断预后有重要价值。本研究主要观察曲美他嗪联合参麦注射液治疗充血性心衰患者的临床疗效及对患者NT-proBNP的影响,现报道如下。

1 资料与方法

1.1 一般资料

选取2014年1月~2016年2月本科收治的心衰患者66例,均符合美国纽约心脏学会(NYHA)心功能分级Ⅱ~Ⅲ级,满足心衰诊断,且左室射血分数<50%。排除由于造血系统、肝肾损害等严重疾病,瓣膜性疾病、心源性休克以及心房颤动等严重心律失常而影响超声心功能评定者。将患者随机分为治疗组和对照组:治疗组38例,其中男20例,女18例,年龄55~81岁,平均年龄(69.8±2.1)岁;对照组28例,其中男16例,女12例,年齡55~80岁,平均年龄(68.9±2.0)岁。两组年龄、性别、心功能状况等资料差异无统计学意义(P>0.05),具有可比性。

1.2 方法

对照组采取常规抗心衰治疗方案(即以心衰治疗的黄金三角为基础:醛固酮受体拮……

登录APP查看全文